Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.38 |
| ▸ | OGFRL1 | Q5TC84 | 10/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19836646 | 0.79 | OPRL1 (0.39) | MEN1KMT2ACYP2D6OPRL1OGFRL1 | |
| SCHEMBL15080543 | 0.79 | — | — | |
| SCHEMBL20206665 | 0.78 | LMNA (0.43) | MEN1KMT2ACYP2D6OPRL1OGFRL1 | |
| SCHEMBL15853818 | 0.74 | OGFRL1 (0.38) | OPRL1OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL15847181 | 0.74 | OGFRL1 (0.38) | OPRL1OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL12436681 | 0.74 | OGFRL1 (0.38) | OPRL1OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL16743560 | 0.74 | OGFRL1 (0.38) | OPRL1OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3046521 | 0.74 | OGFRL1 (0.38) | OPRL1OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL18086595 | 0.74 | OGFRL1 (0.38) | OPRL1OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL17389314 | 0.74 | OGFRL1 (0.38) | OPRL1OGFRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | PURDUE PHARMA L.P. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | QDPR, P2RX4, P2RX5 | MEN1 3416/4885KMT2A 1879/4885CYP2D6 224/4885 |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, OPRK1, QDPR | MEN1 4222/4885KMT2A 1597/4885CYP2D6 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.